Latest Sales Growth News

Volt Group’s HY26 results showcase a surge in revenue and cashflow, powered by the 4D Delta acquisition and strong performances across its subsidiaries.

Coventry Group delivered a 2.8% revenue rise in FY26, but underlying EBITDA fell 23.6% despite a strong second-half recovery. The Group achieved $10 million in cost savings and continues an ongoing strategic review with no immediate decisions.

PT ANTAM (ASX:ATM) posted a 6% increase in net sales to Rp62.71 trillion in the first half of 2026, driven by steady gold, nickel, and bauxite sales. Profit after tax surged 34% to Rp6.91 trillion, supported by improved margins and foreign exchange gains.

Michael Hill International delivered a landmark FY26 with record revenue of AU$655.7 million, a 57% jump in comparable EBIT, and reinstated dividends after a strategic turnaround.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Senetas Corporation reported a 4.7% rise in revenue to $20.2 million for FY2026, achieving a strong $4.4 million operating cash flow turnaround. The company advanced its AI governance platform while maintaining a robust sales pipeline and capital management strategy.

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

McMillan Shakespeare (ASX:MMS) reported a 13.8% rise in underlying net profit after tax and amortisation to $107.9 million for FY26, driven by strong novated lease growth and accelerating electric vehicle adoption.

Hallenstein Glasson delivered a robust FY26 performance with group sales climbing 19.6% to $563 million and net profit before tax surging around 43.5%, buoyed by currency tailwinds and solid operational control.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.